title: Comparison of cisplatin sensitivity and the 18F fluoro-2-deoxy 2 glucose uptake with proliferation parameters and gene expression in squamous cell carcinoma cell lines of the head and neck.
abstract: BACKGROUND
  The survival of patients with locally advanced head and neck cancer is still poor, with 5-year survival rates of 24-35%. The identification of prognostic and predictive markers at the molecular and cellular level could make it possible to find new therapeutic targets and provide "taylor made" treatments. Established cell lines of human squamous cell carcinoma (HNSCC) are valuable models for identifying such markers.The aim of this study was to establish and characterize a series of cell lines and to compare the cisplatin sensitivity and 18F fluoro-2 deoxy 2 glucose (18F-FDG) uptake of these cell lines with other cellular characteristics, such as proliferation parameters and TP53 and CCND1 status.
  
  
  METHODS
  Explant cultures of fresh tumour tissue were cultivated, and six new permanent cell lines were established from 18 HNSCC cases. Successfully grown cell lines were analysed regarding clinical parameters, histological grade, karyotype, DNA ploidy, and index and S-phase fraction (Spf). The cell lines were further characterized with regard to their uptake of 18F-FDG, their sensitivity to cisplatin, as measured by a viability test (crystal violet), and their TP53 and CCND1 status, by fluorescence in situ hybridization (FISH), polymerase chain reaction single-strand conformation polymorphism (PCR-SSCP) with DNA sequencing and, for cyclin D1, by immunohistochemistry.
  
  
  RESULTS
  Patients with tumours that could be cultured in vitro had shorter disease-free periods and overall survival time than those whose tumours did not grow in vitro, when analysed with the Kaplan-Meier method and the log-rank test. Their tumours also showed more complex karyotypes than tumours from which cell lines could not be established. No correlation was found between TP53 or CCND1 status and 18F-FDG uptake or cisplatin sensitivity. However, there was an inverse correlation between tumour cell doubling time and 18F-FDG uptake.
  
  
  CONCLUSIONS
  In vitro growth of HNSCC cells seem to be an independent prognostic factor, with cell lines being more readily established from aggressive tumours, a phenomenon more dependent on the molecular genetic characteristics of the tumour cells than on tumour location or TNM status.
authors.affiliation: Department of Otorhinolaryngology, University Hospital Malmö, SE-205 02 Malmö, Sweden. Eva.Henriksson@skane.se
authors.forename: Eva
authors.initials: E
authors.lastname: Henriksson
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Kjellén
authors.forename: Bo
authors.initials: B
authors.lastname: Baldetorp
authors.forename: Pär-Ola
authors.initials: PO
authors.lastname: Bendahl
authors.forename: Ake
authors.initials: A
authors.lastname: Borg
authors.forename: Eva
authors.initials: E
authors.lastname: Brun
authors.forename: Fredrik
authors.initials: F
authors.lastname: Mertens
authors.forename: Tomas
authors.initials: T
authors.lastname: Ohlsson
authors.forename: Karin
authors.initials: K
authors.lastname: Rennstam
authors.forename: Johan
authors.initials: J
authors.lastname: Wennerberg
authors.forename: Peter
authors.initials: P
authors.lastname: Wahlberg
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D045744:Cell Line, Tumor; D002871:Chromosome Banding; D002945:Cisplatin / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004354:Drug Screening Assays, Antitumor; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics*; D015870:Gene Expression; D016158:Genes, p53; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D009154:Mutation; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics
chemical_list: D000970:Antineoplastic Agents; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D002945:Cisplatin